A cohort study (Zhu et al., 2023) of KOA patients with type 2 diabetes (T2D) reported significantly greater weight loss in the GLP-1 RAs group (mean difference −7.29 kg; 95% CI −8.07 to −6.50 kg; P < 0.001), although 42.06% of GLP-1 RAs users still maintained or gained weight. Here, GLP1R is linked to type 2 diabetes mellitus.